Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

Guggenheim reaffirmed their buy rating on shares of CyberArk Software (NASDAQ:CYBR – Free Report) in a research note issued ...

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

The artist is known for creating futuristic, interactive environments that reflect on contemporary geopolitical and ...

The award is part of the LG Guggenheim Art and Technology Initiative, a five-year, multifaceted collaboration designed to research, honor, and promote artists working at the intersection of art ...

Media artist Kim A-young has been named the recipient of the 2025 LG Guggenheim Award, making her the first Korean artist to ...

As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price ...

Kim’s work ‘raises essential questions about the ethical and emotional implications of living in a technology-driven world’ ...